| abstract |
Provided is a combination therapy of an HSP90 inhibitor targeting HSP90, which is greatly involved in the survival of cancer cells, and another antitumor agent. In addition, the use of the HSP90 inhibitor as a therapeutic effect enhancer for other antitumor agents is provided. The following general formula (1) [Wherein X, Y, A are substituents, Y is an oxygen atom, and m is an integer of 0 to 4] An antitumor agent comprising a combination of a triazole compound (A) and an antitumor taxane compound (B) . [Selection] Figure 1 |